Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients by Peng, Wen Hui et al.
ORIGINAL INVESTIGATION Open Access
Increased serum myeloid-related protein 8/14
level is associated with atherosclerosis in type 2
diabetic patients
Wen Hui Peng
1, Wei Xia Jian
2†, Hai Ling Li
1, Lei Hou
1, Yi Dong Wei
1, Wei Ming Li
1 and Ya Wei Xu
1*
Abstract
Background: Myeloid-related protein 8/14 (MRP8/14) is a stable heterodimer formed by two different calcium-
binding proteins (MRP8 and MRP14). Studies have identified that MRP8/14 regulates vascular inflammation and
serves as a novel marker of acute coronary syndrome. In this study, we evaluated the correlation between serum
levels of MRP8/14, hsCRP, endogenous secretory receptor for advanced glycation end-products (esRAGE) and the
occurrence of coronary artery disease (CAD), or carotid intima-media thickness (IMT) when CAD was not yet
developed in diabetic patients.
Methods: Serum levels of MRP8/14, esRAGE and hsCRP were measured in 375 diabetic patients. Then the results of
those who had CAD were compared against who had not. Also, we investigated the associations between above-
mentioned indicators and IMT of subjects without CAD in both diabetic group and non-diabetic one.
Results: Serum MRP8/14 was significantly higher in CAD than in non-CAD group (9.7 ± 3.6 ug/ml vs. 8.2 ± 3.0 ug/
ml, P < 0.001). It was associated with severity of CAD (r = 0.16, P = 0.026). In non-CAD group, MRP8/14 was
associated with IMT in patients with (r = 0.30, P < 0.001) or without diabetes (r = 0.26, P = 0.015). The areas under
the curves of receiver operating characteristic for CAD were 0.63 (95% CI 0.57-0.68) for MRP8/14, 0.76 (95% CI 0.71-
0.81) for hsCRP and 0.62 (95% CI 0.56 -0.67) for esRAGE.
Conclusion: In summary, we report that diabetic patients with CAD had elevated plasma MRP8/14 levels which
were also positively correlated with the severity of CAD and carotid IMT in patients without clinically overt CAD.
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Introduction
Diabetes mellitus (DM) has been regarded as an impor-
tant risk factor of cardiovascular diseases, and cardiovas-
cular disease accounts for almost 70% deaths of diabetic
patients [1]. The increased oxidative stress and inflam-
mation are believed to be the pivotal mechanisms for
diabetic cardiovascular complications [2].
Myeloid-related protein 8/14 (MRP8/14) is a stable
heterodimer formed by two calcium-binding proteins
(MRP8 and MRP14, also termed as Calgranulin A and
Calgranulin B or S-100 calcium binding protein A8 and
S100 calcium binding protein A9, respectively) [3].
MRP8 and MRP14, belonging to the S100 protein
family, are expressed in activated human granulocytes
and macrophages in inflammatory lesions, and have
multiple functions such as activating NADPH oxidase
[4-6], toll-like receptor 4 and receptor for advanced gly-
cation endproducts (RAGE) [7,8] which are vital signal-
ing pathways involved in the pathogenesis of micro- and
macro-vascular complications in diabetes.
As mentioned above, MRP8/14 is involved in dia-
betic vascular complications, thus it is reasonable to
propose that serum level of MRP8/14 would be a valu-
able index in assessing the risk of diabetic patients
with developed cardiovascular diseases. Therefore, we
investigated the association between the serum level of
MRP8/14 and incidence of angiographically confirmed
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Meanwhile, we also attempted to explore the relation
of serum MRP8/14 and carotid intima-media thickness
(IMT) in people without CAD regardless of the pre-
sence of DM, with IMT being an early diagnostic
index of atherosclerosis [9].
Being identified as a ligand for RAGE [10], MRP8/14
is believed to facilitate the detrimental effects of RAGE
through advanced end glycation products [11]. Endogen-
ous secretory RAGE (esRAGE) is the C truncated iso-
form of RAGE, which is able to prevent advanced
glycation endproducts injury by acting as a decoy [12].
Previous studies of both our group and other research-
ers had shown that serum esRAGE level decreased in
patients with diabetes and cardiovascular disease
[13-15]. Therefore we also evaluated the serum levels of
esRAGE and high sensitivity C reactive protein (hsCRP)
in diabetic patients so as to determine their roles in
inflammation and vascular damage.
Methods
All subjects were local residents of Han ethnicity in
Shanghai. The protocol was approved by the hospital’s
Ethics Committee and written informed consents were
obtained from all participants. This study included 375
consecutive patients with T2DM and 87 patients with-
out T2DM or CAD in Department of Cardiology of
Shanghai Tenth People’s Hospital (faciliated to Tongji
University, School of Medicine) and Department of
Endocrinology of Xinhua Hospital (faciliated to Shang-
hai Jiaotong University, School of Medicine). Patients
without angiographically significant coronary stenosis
were recruited for carotid ultrasound examination. Type
2 diabetes mellitus was diagnosed according to WHO
standard or current intake of hypoglycemic agents [16].
Hypertension was defined as blood pressure ≥140/90
mmHg or having a history of receiving antihypertensive
therapy. Those who had been diagnosed with acute
myocardial infarction, systemic inflammatory disorders,
severe heart failure (left ventricular ejection fraction
<30%), advanced renal insufficiency or malignant tumor
were excluded.
Coronary angiography and quantitative analysis
Coronary angiography was performed by using standard
Judkins technique or through a radial approach. Signifi-
cant CAD was defined as the presence of luminal dia-
meter stenosis ≥50% in the left anterior descending
artery, left circumflex artery, right coronary artery, or
their main branches. Left main trunk stenosis (≥50%
luminal narrowing) was considered as a 2-vessel disease.
For coronary lesion analysis, we used quantitative cor-
onary analyses (QCA, Centricity Cardiology CA 1000.
v1.0, USA) as mentioned before [17]. To put it briefly,
end-diastolic frames from angiograms were selected
with identical angulations that best showed the stenosis
at its most severe degree with minimal foreshortening
and branch overlap. Arterial segments were defined
from the images acquired on the basis of the anatomic
location of proximal and dist a ls i d eb r a n c h e s .T h ec o r -
onary artery segments analysis included all those pla-
ques with a reference diameter ≥1.5 mm and a stenosis
≥20%. Using the outer diameter of the contrast-filled
catheter as the calibration, the minimal lumen diameter
in diastole was measured. Coronary artery score was cal-
culated from per-patient average of the minimal lumen
diameter of all the measured segments in observed cor-
onary artery, and cumulative coronary obstruction was
the sum of all percent diameter stenoses in standard
index unit (50% = 0.50) [18].
Carotid artery ultrasound
The carotid ultrasound examination was carried out by
using Vivid-7 system (GE Vingmed Sound AS, Horton,
Norway) with a scanning frequency of 5-12 MHz in B-
mode. Operator was blind to the study group and did
the ultrasound exam followin gt h es a m ep r o t o c o l .T h e
flow divider between the internal and external carotid
arteries was identified, and the common carotid arteries
were explored starting from 1 cm below the flow divi-
der. Measurements were obtained by tracing the leading
edge of the lumen-intima and the media-adventitia
interfaces. Maximum right and left IMTs were averaged
to obtain the carotid IMT measurement.
Biochemical investigations
Blood samples were collected after overnight fasting in
hospital and stored at -80°C. Serum glucose and lipid
profiles (total cholesterol, low-density lipoprotein-cho-
lesterol, high-density lipoprotein cholesterol, lipoprotein
(a) and triglycerides) were measured (HITACHI 912
Analyser, Roche Diagnostics, Germany). Serum concen-
trations of glycosylated hemoglobin A1c (HbA1c), blood
urea nitrogen (BUN), creatinine, and uric acid were
assessed by standard methods. Renal function was evalu-
ated according to the estimated creatinine clearance rate
(CrCl) derived from Cockroft-Gault formula, where
CrCl (ml/min) = ([140-age] × weight [kg])/(serum crea-
tinine [mg/dl] × 72), corrected in women by a factor of
0.85 [19]. HsCRP and esRAGE were determined by
ELISA kit as indicated earlier [15]. MRP8/14 level was
also assessed using ELISA kit (Bühlmann Laboratories,
Schönenbuch, Switzerland).
Statistical analysis
Continuous variables were expressed as mean ± stan-
dard deviation (SD), and categorical variables were pre-
sented as frequencies. Normal distribution was
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transformation was performed on the continuous vari-
ables of non-normal distribution before statistical calcu-
lations that requested normal distribution. Comparisons
between groups were made using unpaired t tests, analy-
sis of variance or nonparametric Mann-Whitney U test,
when appropriate. Qualitative variables were compared
using Chi-square test. Pearson’s correlations were used
to test the relationship between continuous variables.
Receiver operating characteristic (ROC) analysis was
also carried out on the serum levels of the MRP8/14,
hsCRP and esRAGE for the differentiation of CAD.
Multivariate logistic regression model was constructed
to assess the independent determinants of CAD. A 2-
sided probability level of ≤0.05 was considered signifi-
cant. All analyses were done with SPSS for Windows
13.0 (SPSS Inc, Chicago, Illinois).
Results
Baseline characteristics
General characteristics of patients were shown in Table
1. Patients in CAD and non-CAD groups had similar
waist-to-hip ratio, systolic blood pressure, diastolic
blood pressure, diabetic duration and proportion of
smoking, hypertension, and stroke. But CAD patients
were older and had a higher percentage of male than
non-CAD group. As for lipid profile, CAD patients had
higher serum lipoprotein (a) and lower HDL levels (P <
0.05). There were insignificant differences in fasting glu-
cose and 2 h postprandial glucose between two groups.
CAD group had worse renal function (33.5 ± 14.6 ml/
min vs. 44.2 ± 18.6 ml/min, P <0 . 0 0 1 ) .S e r u me s R A G E
in CAD group was lower, while hsCRP and MRP8/14
were significantly higher than non-CAD group (0.26 ±
0.18 ng/ml vs. 0.31 ± 0.16 ng/ml for esRAGE; 15.4 ±
15.9 mg/L vs. 6.7 ± 11.1 mg/L for hsCRP; 9.7 ± 3.6 ug/
ml vs. 8.2 ± 3.0 ug/ml for MRP8/14, all P < 0.05).
The relationship between MRP8/14 and diabetic CAD
We compared the diagnostic value for CAD of serum
MRP8/14 complex level with esRAGE and hsCRP levels
in T2DM patients by ROC curves. The areas under the
curves were 0.63 (95% confidence interval (CI): 0.57-
0.68) for MRP8/14, 0.77 (95% CI: 0.72-0.81) for hsCRP
and 0.62 for esRAGE (95% CI: 0.56-0.67). Given a cut-
off value of 10.9 mg/ml for MRP8/14, serum MRP8/14
complex level was able to significantly distinguish CAD
patients among diabetic subjects, with sensitivity of
38.5% and specificity of 85.3% (P < 0.05).
In multivariate logistic regression analysis, serum
MRP8/14 was significantly associated with the presence
of CAD (OR = 1.13, 95% CI [1.050-1.225], P = 0.001),
and it was independent of traditional risk factors for
CAD (see Table 2).
Relationship of MRP8/14 with clinical, biochemical
parameters, and CAD severity
Correlation analyses were performed to evaluate
potential associations between serum MRP8/14 level
and clinical measurements. A significant linear corre-
lation existed between serum MRP8/14 level and
waist-to-hip ratio, renal function, hsCRP level, respec-
tively, in the population studied (see Table 3, all P <
0.05).
In CAD cases, serum MRP8/14 and hsCRP levels were
positively associated with severity of CAD (r =0 . 1 6 ,P =
0.026; r =0 . 1 5 ,P = 0.028, respectively). However,
esRAGE showed negative correlation with severity of
CAD with weak significance (r =- 0 . 1 2 ,P =0 . 0 9 5 )( S e e
Table 4). In addition, we found MRP8/14 and hsCRP
levels were also strongly associated with coronary artery
score and cumulative coronary obstruction (r =0 . 2 3 ,P
= 0.009; r = 0.21, P = 0.010, respectively).
Table 1 Clinical characteristics
No CAD CAD P
Age (years) 64 ± 10 68 ± 10 <0.001
Sex (men, %) 90 (52.9%) 130 (63.4%) 0.04
BMI (kg/m2) 25.7 ± 4.0 25.0 ± 3.2 0.037
Waist-to-hip ratio 0.93 ± 0.07 0.92 ± 0.08 NS
Systolic BP (mmHg) 137 ± 19 139 ± 23 NS
Diastolic BP (mmHg) 79 ± 11 78 ± 12 NS
Smoker (n, %) 44 (25.9%) 51 (24.9%) NS
Hypertension (n, %) 113 (66.5%) 155 (75.6%) 0.051
Stroke (n, %) 17 (10.0%) 20 (9.8%) NS
Duration of diabetes (years) 8 ± 7 8 ± 7 NS
Total Cholesterol (mmol/L) 4.55 ± 1.08 4.41 ± 1.16 NS
Triglyceride (mmol/L) 1.98 ± 1.70 1.98 ± 1.45 NS
HDL Cholesterol (mmol/L) 1.19 ± 0.32 1.14 ± 0.34 0.030
LDL Cholesterol (mmol/L) 2.73 ± 0.78 2.64 ± 0.91 NS
lipoprotein (a) (mg/L) 102 ± 158 238 ± 186 <0.001
BUN (mmol/L) 6.3 ± 2.6 7.2 ± 6.2 NS
Creatinine (umol/L) 74.5 ± 28.1 91.1 ± 39.6 <0.001
CrCl (ml/min) 44.2 ± 18.6 33.5 ± 14.6 <0.001
Uric acid (mg/L) 74.5 ± 28.1 91.1 ± 39.6 0.034
Fasting glucose (mmol/L) 7.7 ± 2.5 7.3 ± 2.7 NS
2 h Postprandial glucose (mmol/L) 13.1 ± 4.7 12.9 ± 4.2 NS
HbA1c (%) 8.1 ± 2.0 7.6 ± 1.4 0.012
Fasting insulin (mU/L) 10.1 ± 10.8 8.3 ± 7.8 NS
2 h Postprandial insulin (mU/L) 48.2 ± 48.7 39.4 ± 35.5 NS
hsCRP (mg/L) 6.7 ± 11.1 15.4 ± 15.9 <0.001
esRAGE (ng/ml) 0.31 ± 0.16 0.26 ± 0.18 <0.001
MRP8/14 (ug/ml) 8.2 ± 3.0 9.7 ± 3.6 <0.001
Data are presented as mean ± SD or number (percent).
BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL, low-
density lipoprotein cholesterol; BUN, blood urea nitrogen; CrCl: creatinine
clearance; HbA1c, hemoglobin A1c; hsCRP, high sensitive C-reactive protein;
esRAGE, endogenous secretory receptor for advanced glycation end products;
MRP8/14, Myeloid-related protein 8/14
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parameters
In univariate analysis, MRP8/14 (r =0 . 3 0 ,P < 0.001)
(Figure 1), hsCRP (r = 0.23, P =0 . 0 0 3 ) ,a n d2hp o s t -
prandial glucose (r = 0.16, P = 0.032) levels were posi-
tively correlated with carotid IMT in non-CAD group.
In multiple regression analysis after adjustment of age,
sex, hypertension, etc., MRP8/14 and hsCRP, but not 2
h postprandial glucose level, were considered indepen-
dent determinants for IMT in diabetic patients without
CAD (P < 0.05).
In subjects with neither DM nor angiographically con-
firmed CAD, we also found positive correlation between
carotid IMT and serum MRP8/14 level (r = 0.26, P =
0.015).
Discussion
To date, there have been few reports focusing on the
clinical importance of MRP8/14 in diabetic complica-
tions. In this study, we found that diabetic patients with
angiographically confirmed CAD had elevated serum
MRP8/14 level. Moreover, MRP8/14 was highly asso-
ciated with not only the severity of CAD, but also the
early atherosclerotic marker, the carotid IMT in patients
without CAD.
MRP8/14 and inflammatory vascular disease
Elevated serum MRP8/14 level was found in several
chronic inflammatory conditions, including rheumatoid
arthritis, allograft rejections, and inflammatory bowel
and lung diseases [20-25]. MRP8/14 was not only
involved in promoting the inflammatory response in
infected lesions but also identified as a potent amplifier
of inflammation during autoimmune reaction [10].
MRP8/14 was also reported to be expressed in human
atherosclerotic plaques, especially in rupture-prone
lesions [26]. Recent studies identified that MRP8/14
broadly regulated vascular inflammation and contributed
to the biological response to vascular injury [27]. Clini-
cal studies showed MRP8/14 as a novel marker of acute
coronary syndromes and a predicting factor for future
cardiovascular events [22,23,26].
Some studies suggested that MRP8/14 participated in
diabetic vascular disease. Serum level of MRP8/14 was
increased in type 1 diabetes mellitus thus enhanced
adhesion of circulating monocytes to fibronectinin [28],
and serum MRP8/14 level was found to be an indicator
of microcirculatory defects in diabetic nephropathy [29].
In this study, we further confirmed that compared with
non-CAD diabetic patients, serum MRP8/14 level was
increased in patients with CAD. More interestingly,
serum MRP8/14 was not only associated with severity of
CAD, but also with carotid IMT in subjects without
CAD. Measurement of carotid IMT was determined
with good and comparable reproducibility in both sub-
jects with T2DM and those without [30]. Patients with
diabetes often develop CAD in their early stages, how-
ever the early diagnosis of CAD in diabetic patients is
often missed as these patients are always asymptomatic
or having atypical chest pain. The availability of a sensi-
tive and specific early biomarker for diabetic athero-
sclerosis would be highly desirable for the diagnosis and
Table 3 Relation of MRP8/14 with other parameters
rP
Body mass index 0.05 NS
Waist-to-hip ratio 0.11 0.030
Total Cholesterol -0.03 NS
Triglyceride 0.03 NS
HDL Cholesterol -0.01 NS
LDL Cholesterol -0.02 NS
lipoprotein (a) 0.10 0.055
BUN 0.11 0.030
Creatinine 0.14 0.008
Uric acid -0.02 NS
Fasting glucose -0.01 NS
2 h Postprandial glucose 0.00 NS
HbA1c (%) 0.01 NS
Fasting insulin -0.05 NS
2 h Postprandial insulin -0.04 NS
hsCRP 0.15 0.003
esRAGE -0.05 NS
coronary artery score 0.23 0.009
cumulative coronary obstruction 0.21 0.010
HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein
cholesterol; BUN, blood urea nitrogen; HbA1c, hemoglobin A1c; hsCRP, high
sensitive C-reactive protein; esRAGE, endogenous secretory receptor for
advanced glycation end products; MRP8/14, Myeloid-related protein 8/14
Table 2 Multivariable regression analysis of independent
determinants of CAD in Type 2 diabetes mellitus
Odds ratio 95% Confidence interval P
Age 1.02 0.99-1.05 NS
Male 1.49 0.84-2.65 NS
Body mass index 0.926 0.863-0.994 0.034
Smoking 0.983 0.531-1.820 NS
Hypertension 1.624 0.925-2.851 NS
Triglyceride 1.035 0.877-1.222 NS
Total Cholesterol 0.966 0.703-1.327 NS
LDL Cholesterol 0.960 0.651-1.415 NS
HDL Cholesterol 0.696 0.319-1.517 NS
Creatinine 1.009 1.00-1.02 NS
hsCRP 1.10 1.061-1.138 <0.001
esRAGE 0.211 0.054-0.826 0.025
MRP8/14 1.13 1.050-1.225 0.001
HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein
cholesterol; hsCRP: high-sensitivity C-reactive protein; esRAGE, endogenous
secretory receptor for advanced glycation end products; MRP8/14, Myeloid-
related protein 8/14
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strong association between serum MRP8/14 and carotid
IMT in patients without CAD further confirmed serum
MRP8/14 as a novel marker for diabetic vasculopathy
even in its early stage.
It should be noted that although MRP8/14 was
strongly associated with diabetic vasculopathy, the diag-
nostic value of MRP8/14 for CAD was limited. In ROC
analysis, the area under the curve of MRP8/14 was only
0 . 6 3 ,w h i c hw a sn o ts u p e r i o rt ot h a to fh s C R P .I tm a y
partly due to the medication of diabetic patients, such
as statin and hypoglycemic drugs. Since our study was a
cross-section study, the strong association between
MRP8/14 and IMT and its clinical implication is yet to
be confirmed by further cohorts study.
The association of MRP8/14 with renal function and other
serum factors
Another question which should be taken into account
was that whether or not the elevated serum MRP8/14
level was due to worse renal function in CAD group.
Previous study showed that serum MRP8/14 was related
to diabetic nephropathy [29]. In our study, we also
found strong association between MRP8/14 and CrCl.
By multivariate regression analysis, we found that serum
MRP8/14 was a determinant for CAD even after adjust-
ment of renal function, which suggested that detrimen-
tal effect of MRP8/14 in macrovascular disease was
independent of renal function.
Although serum MRP8/14 level was increased in dia-
betic microvascular or macrovascular diseases [29], pre-
vious studies did not find its increase in type 2 diabetes
compared to that in normal subjects. In our study, we
found no correlation between serum MRP8/14 and para-
meters related to glucose homeostasis both in univariate
and multivariate regression analysis; nevertheless, serum
MRP8/14 was positively associated with hsCRP. This sug-
gested that the glucose homeostatic effects on serum
MRP8/14 concentration were minimal and systemic
inflammation should be the principal factor for regulating
serum MRP8/14 expression [28]. Moreover, we did not
find any association between serum MRP8/14 and
HbA1c–the representative marker of systemic glycation,
or serum esRAGE–a selective splice isoform of RAGE
showing functions such as inhibiting atherogenesis and
mitigating progression of atherosclerotic lesion in diabetic
mice [31,32]. The lacking of association between MRP8/14
and glucose or glycation products further confirmed that
regulation of serum MRP8/14 level in diabetic complica-
tions was independent of glucose metabolism.
Conclusions
In summary, we report that diabetic patients with CAD
had elevated plasma MRP8/14 levels which were also
positively correlated with the severity of CAD and caro-
tid IMT in patients without clinically overt CAD. There-
fore, routine assessment of MRP8/14 could be
recommended in diabetic patients who were considered
as the high risk population of CAD, and this may pro-
vide physicians with another effective method of evalu-
ating vascular risks in diabetic patients.
Abbreviations
BUN: blood urea nitrogen; CAD: coronary artery disease; CI: confidence
interval; CrCl: creatinine clearance; DM: diabetes mellitus; esRAGE:
endogenous secretory receptor for advanced glycation endproducts; HbA1c:
Table 4 Association of CAD severity with biochemistry characteristics
1 vessel disease 2 vessel disease 3 vessel disease 4 vessel disease r value P value for trend
esRAGE (ng/ml) 0.29 ± 0.18 0.24 ± 0.18 0.26 ± 0.17 0.16 ± 0.06 -0.12 0.095
hsCRP (mg/L) 12.2 ± 10.2 14.8 ± 13.6 16.7 ± 17.2 22.3 ± 16.3 0.15 0.028
MRP8/14 (ug/ml) 9.0 ± 3.1 9.9 ± 3.9 10.3 ± 3.6 10.8 ± 4.0 0.16 0.026
Data are presented as mean ± SD
hsCRP: high-sensitivity C-reactive protein; esRAGE, endogenous secretory receptor for advanced glycation end products; MRP8/14, Myeloid-related protein 8/14
Figure 1 Correlation between MRP8/14 concentration and
carotid IMT in diabetic patients without CAD. Positive correlation
(Spearman’s rho) was observed between serum MRP8/14
concentration and carotid intima-media thickness in diabetic
patients without CAD, r = 0.30, P < 0.001. cIMT:carotid intima-media
thickness; MRP8/14, Myeloid-related protein 8/14
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